NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile
Oncology Reports · 2023
DOI: 10.3892/or.2023.8542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2023. Verfasst von María Cecilia Lira und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Research Alfredo Lanari, School of Medicine, University of Buenos Aires, Ciudad Autónoma de Buenos Aires 1427, Argentina. Hauptthemen laut MEDLINE: Breast Neoplasms, Nuclear Receptor Coactivator 3. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Research Alfredo Lanari, School of Medicine, University of Buenos Aires, Ciudad Autónoma de Buenos Aires 1427, Argentina.
- Laboratory of Chronobiology, National University of Quilmes, Quilmes, Buenos Aires 1876, Argentina.
Zitieren
APA
Lira, M. C., Rosa, F. D., Aiello, I., Machado, M. S., Palma, A. G., Paz, L., Güemes, M. C. S., Burlando, S., Azurmendi, P. J., Paladino, N., Costas, M. A., & Rubio, M. F. (2023). NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile. Oncology Reports. https://doi.org/10.3892/or.2023.8542
Vancouver
Lira MC, Rosa FD, Aiello I, Machado MS, Palma AG, Paz L, et al. NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile. Oncology Reports. 2023. doi:10.3892/or.2023.8542
BibTeX
@article{Lira2023,
author = {Lira, María Cecilia and Rosa, Francisco D and Aiello, Ignacio and Machado, Mileni Soares and Palma, Alejandra G and Paz, Leonardo and Güemes, María Cecilia Salazar and Burlando, Silvia and Azurmendi, Pablo J and Paladino, Natalia and Costas, Mónica A and Rubio, María Fernanda},
title = {NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile},
journal = {Oncology Reports},
year = {2023},
doi = {10.3892/or.2023.8542}
}
EUVIMED